Altered pharmacokinetics in patients with major burns may result in serum antibiotic concentrations below those required to be effective against the common pathogens encountered in burns patients. The major changes in the fluid volumes of key body compartments, which occur with a large burn, may increase the apparent volume of distribution of a drug, thereby lowering its concentration when a standard dose is given. In addition, the observed increase in renal blood flow reported in burns patients, because of the change in cardiac output, may result in a higher drug clearance and a shorter elimination half-life. As a consequence, studies have recommended higher doses or more frequent dosing or both for some antibiotics in patients with major ...
Objectives: To develop a population model to describe the pharmacokinetics (PK) of intravenous merop...
Patients suffering major burn injury represent a unique population of critically ill patients. Wides...
Antibiotic treatment of critically ill patients remains a significant challenge. Optimal antibacteri...
Profound pharmacokinetic alterations involving volume of distribution and clearance may impair the a...
Multiple organ failure (MOF) and compromised immune function, which results in increased susceptibil...
As pharmacokinetics after burn trauma are difficult to predict, we conducted a 3-year prospective, m...
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may resu...
Burn injury patients are a special subset of patients with an increased likelihood of developing inf...
PURPOSE: Adequate empirical antibiotic dose selection for critically ill burn patients is difficult ...
Objectives: To determine how long single-dose prophylactic antibiotic regimens for burns surgery mai...
BACKGROUND: Aminoglycosides are mandatory in the treatment of severe infections in burns. However, t...
Item does not contain fulltextINTRODUCTION: Pharmacokinetics of drugs can be significantly altered i...
Objectives: To determine how long single-dose prophylactic antibiotic regimens for burns surgery mai...
A 35-year-old patient in intensive care with severe burn injury developed episodes of sepsis. Blood ...
Objectives To develop a population model to describe the pharmacokinetics (PK) of intravenous merope...
Objectives: To develop a population model to describe the pharmacokinetics (PK) of intravenous merop...
Patients suffering major burn injury represent a unique population of critically ill patients. Wides...
Antibiotic treatment of critically ill patients remains a significant challenge. Optimal antibacteri...
Profound pharmacokinetic alterations involving volume of distribution and clearance may impair the a...
Multiple organ failure (MOF) and compromised immune function, which results in increased susceptibil...
As pharmacokinetics after burn trauma are difficult to predict, we conducted a 3-year prospective, m...
Critical illness caused by burn and sepsis is associated with pathophysiologic changes that may resu...
Burn injury patients are a special subset of patients with an increased likelihood of developing inf...
PURPOSE: Adequate empirical antibiotic dose selection for critically ill burn patients is difficult ...
Objectives: To determine how long single-dose prophylactic antibiotic regimens for burns surgery mai...
BACKGROUND: Aminoglycosides are mandatory in the treatment of severe infections in burns. However, t...
Item does not contain fulltextINTRODUCTION: Pharmacokinetics of drugs can be significantly altered i...
Objectives: To determine how long single-dose prophylactic antibiotic regimens for burns surgery mai...
A 35-year-old patient in intensive care with severe burn injury developed episodes of sepsis. Blood ...
Objectives To develop a population model to describe the pharmacokinetics (PK) of intravenous merope...
Objectives: To develop a population model to describe the pharmacokinetics (PK) of intravenous merop...
Patients suffering major burn injury represent a unique population of critically ill patients. Wides...
Antibiotic treatment of critically ill patients remains a significant challenge. Optimal antibacteri...